The Food and Drug Association (FDA) is reviewing its restrictions on the abortion-inducing drug mifepristone, according to a May 7 court filing in a suit challenging the regulations.
The American Civil Liberties Union (ACLU), which is bringing suit against the FDA’s current rules restricting the drug, celebrated the agency’s decision in a statement Friday:
“The FDA’s decision to review these senseless restrictions on mifepristone — though long overdue — is a critical move towards ensuring that patients can access this safe, effective medication without needless obstacles,” said Julia Kaye, staff attorney at the ACLU Reproductive Freedom Project.
The news comes after the FDA lifted one restriction on the abortion pill in April, allowing it to be sent by mail for at-home abortions.
Mifepristone, also called Mifeprex, is currently subject to REMS (Risk Evaluation and Mitigation Strategies) restrictions, which “continues to be necessary to ensure the safe use of Mifeprex,” according to the FDA website: